Richard C. Breeden - Jun 2, 2022 Form 4 Insider Report for STERIS plc (STE)

Role
Director
Signature
/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney
Stock symbol
STE
Transactions as of
Jun 2, 2022
Transactions value $
$104,134
Form type
4
Date filed
6/6/2022, 04:35 PM
Previous filing
Aug 12, 2021
Next filing
Aug 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STE Ordinary Shares Options Exercise $104K +3.22K +9.2% $32.36 38.2K Jun 2, 2022 Direct
holding STE Ordinary Shares 27.2K Jun 2, 2022 See Footnotes Below F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STE Director Stock Option (right to buy) Options Exercise -3.22K -100% 0 Jun 2, 2022 Ordinary Shares 3.22K $32.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
F2 Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
F3 This option to purchase 3,218 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,218 ordinary shares for $32.36 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.